Roche: Tecentriq cuts risk of lung cancer death
(CercleFinance.com) - Roche's Tecentriq plus chemotherapy reduces the risk of the cancer worsening or death in the initial treatment of people with advanced squamous lung cancer, a Phase III study showed.
The trial enrolling 1,021 people met its co-primary endpoint of progression-free survival in the initial treatment of people with advanced squamous non-small cell lung cancer (NSCLC), the Swiss drugmaker said.
Lung cancer is the leading cause of cancer death globally, with squamous non-small cell lung cancer proving particularly difficult to treat.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The trial enrolling 1,021 people met its co-primary endpoint of progression-free survival in the initial treatment of people with advanced squamous non-small cell lung cancer (NSCLC), the Swiss drugmaker said.
Lung cancer is the leading cause of cancer death globally, with squamous non-small cell lung cancer proving particularly difficult to treat.
Copyright (c) 2018 CercleFinance.com. All rights reserved.